Laboratorios Farmaceuticos Rovi, S.A. – LSE:0ILL.L
Laboratorios Farmaceuticos Rovi, S.A. stock price today
Laboratorios Farmaceuticos Rovi, S.A. stock price monthly change
Laboratorios Farmaceuticos Rovi, S.A. stock price quarterly change
Laboratorios Farmaceuticos Rovi, S.A. stock price yearly change
Laboratorios Farmaceuticos Rovi, S.A. key metrics
Market Cap | 3.11B |
Enterprise value | 3.21B |
P/E | 22.32 |
EV/Sales | 4.13 |
EV/EBITDA | 15.04 |
Price/Sales | 4.03 |
Price/Book | 6.94 |
PEG ratio | 1.71 |
EPS | 2.61 |
Revenue | 779.05M |
EBITDA | 203.25M |
Income | 137.83M |
Revenue Q/Q | -25.02% |
Revenue Y/Y | -4.26% |
Profit margin | 19.03% |
Oper. margin | 24.52% |
Gross margin | 58.67% |
EBIT margin | 24.52% |
EBITDA margin | 26.09% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeLaboratorios Farmaceuticos Rovi, S.A. stock price history
Laboratorios Farmaceuticos Rovi, S.A. stock forecast
Laboratorios Farmaceuticos Rovi, S.A. financial statements
| Jun 2023 | 179.21M | 19.18M | 10.71% |
|---|---|---|---|
| Sep 2023 | 214.02M | 52.18M | 24.38% |
| Dec 2023 | 234.63M | 51.50M | 21.95% |
| Mar 2024 | 151.17M | 14.96M | 9.9% |
| 2027 | 1.25B | 343.95M | 27.32% |
|---|
Analysts Price target
Financials & Ratios estimates
| Payout ratio | 46.64% |
|---|
| 2019 | 0.33% |
|---|---|
| 2020 | 0.45% |
| 2021 | 0.53% |
| 2022 | 2.61% |
| 2023 | 2.13% |
| Jun 2023 | 899832000 | 378.48M | 42.06% |
|---|---|---|---|
| Sep 2023 | 830725000 | 276.08M | 33.23% |
| Dec 2023 | 799884000 | 255.03M | 31.88% |
| Mar 2024 | 778663000 | 254.88M | 32.73% |
| Jun 2023 | 28.63M | -13.24M | -3.03M |
|---|---|---|---|
| Sep 2023 | 123K | -8.90M | -88.65M |
| Dec 2023 | 61.10M | -26.46M | -65.69M |
| Mar 2024 | 15.54M | -9.15M | -18.62M |
Laboratorios Farmaceuticos Rovi, S.A. alternative data
| Aug 2023 | 1,993 |
|---|---|
| Sep 2023 | 2,037 |
| Oct 2023 | 2,037 |
| Nov 2023 | 2,037 |
| Dec 2023 | 1,993 |
| Jan 2024 | 1,993 |
| Feb 2024 | 1,993 |
| Mar 2024 | 1,925 |
| Apr 2024 | 1,925 |
| May 2024 | 1,925 |
| Jun 2024 | 1,925 |
| Jul 2024 | 1,925 |
Laboratorios Farmaceuticos Rovi, S.A. other data
| Insider | Compensation |
|---|---|
Mr. Juan López-Belmonte Encina Chief Executive Officer & Director | $481,000 |
Mr. Javier López-Belmonte Encina Second Deputy Chairman & Chief Financial Officer | $357,000 |
Mr. Iván López-Belmonte Encina First Deputy Chairman & Head of Corporation Devel. | $356,000 |
Ms. Rosario Perucha Pérez Marketing Mang. | |
Mr. Francisco Javier Angulo García HR Mang. | |
Mr. Gabriel Núñez Fernández Sec. | |
Mr. Ignacio Zarzalejos Toledano Deputy Sec. | |
Ms. Mercedes Benítez del Castillo Sánchez Legal Department Mang. | |
Mr. Fernando Martínez Morales Director of Sales |
-
What's the price of Laboratorios Farmaceuticos Rovi, S.A. stock today?
One share of Laboratorios Farmaceuticos Rovi, S.A. stock can currently be purchased for approximately $72.64.
-
When is Laboratorios Farmaceuticos Rovi, S.A.'s next earnings date?
Unfortunately, Laboratorios Farmaceuticos Rovi, S.A.'s (0ILL.L) next earnings date is currently unknown.
-
Does Laboratorios Farmaceuticos Rovi, S.A. pay dividends?
Yes, Laboratorios Farmaceuticos Rovi, S.A. pays dividends and its trailing 12-month yield is 1.44% with 47% payout ratio. The last Laboratorios Farmaceuticos Rovi, S.A. stock dividend of $0.08 was paid on 4 Jul 2019.
-
How much money does Laboratorios Farmaceuticos Rovi, S.A. make?
Laboratorios Farmaceuticos Rovi, S.A. has a market capitalization of 3.11B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 1.44% to 829.51M US dollars.
-
What is Laboratorios Farmaceuticos Rovi, S.A.'s stock symbol?
Laboratorios Farmaceuticos Rovi, S.A. is traded on the LSE under the ticker symbol "0ILL.L".
-
What is Laboratorios Farmaceuticos Rovi, S.A.'s primary industry?
Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.
-
How do i buy shares of Laboratorios Farmaceuticos Rovi, S.A.?
Shares of Laboratorios Farmaceuticos Rovi, S.A. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Laboratorios Farmaceuticos Rovi, S.A.'s key executives?
Laboratorios Farmaceuticos Rovi, S.A.'s management team includes the following people:
- Mr. Juan López-Belmonte Encina Chief Executive Officer & Director()
- Mr. Javier López-Belmonte Encina Second Deputy Chairman & Chief Financial Officer()
- Mr. Iván López-Belmonte Encina First Deputy Chairman & Head of Corporation Devel.()
- Ms. Rosario Perucha Pérez Marketing Mang.
- Mr. Francisco Javier Angulo García HR Mang.
- Mr. Gabriel Núñez Fernández Sec.
- Mr. Ignacio Zarzalejos Toledano Deputy Sec.
- Ms. Mercedes Benítez del Castillo Sánchez Legal Department Mang.
- Mr. Fernando Martínez Morales Director of Sales
-
How many employees does Laboratorios Farmaceuticos Rovi, S.A. have?
As Jul 2024, Laboratorios Farmaceuticos Rovi, S.A. employs 1,925 workers.
-
When Laboratorios Farmaceuticos Rovi, S.A. went public?
Laboratorios Farmaceuticos Rovi, S.A. is publicly traded company for more then 14 years since IPO on 24 Feb 2011.
-
What is Laboratorios Farmaceuticos Rovi, S.A.'s official website?
The official website for Laboratorios Farmaceuticos Rovi, S.A. is rovi.es.
-
How can i contact Laboratorios Farmaceuticos Rovi, S.A.?
Laboratorios Farmaceuticos Rovi, S.A. can be reached via phone at +34 910 21 30 00.
Laboratorios Farmaceuticos Rovi, S.A. company profile:
Laboratorios Farmaceuticos Rovi, S.A.
rovi.esLSE
2,111
Medical - Pharmaceuticals
Healthcare
Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company distributes other products that are licensed from other laboratories. Its principal products include Hibor, a low-molecular-weight heparin to prevent and treat venous thromboembolic disease; Enoxaparin biosimilar Becat, a low-molecular-weight heparin; Neparvis to treat symptomatic chronic heart failure with reduced ejection in adult patients; Absorcol, Vytorin, and Orvatez to diet in patients with hypercholesterolemia; Hirobriz Breezhaler and Ulunar Breezhaler that are long-acting bronchodilators for the maintenance treatment of chronic obstructive pulmonary diseases; Volutsa for treatment of moderate to severe storage systems symptoms and voiding symptoms associated with benign prostatic hyperplasia in men who are not responding adequately to monotherapy treatment; and Medikinet and Medicebrán to treat attention deficit hyperactivity disorder in children and teenagers. The company also markets various hospital products for imaging diagnosis, such as Iomeron and Iopamiro for computed tomography and intervention; Multihance and Prohance for magnetic resonance imaging; Sonovue for ultrasounds; and EmpowerCTA+, EmpowerMR, and CT Exprès that are contrast injection systems and compatible disposable material. It provides non-prescription pharmaceutical products; and contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, hard capsules, and sachets. The company serves wholesalers, doctors, nursing staff, pharmacists, and patients. It has a collaboration with Moderna, Inc. for manufacturing mRNA COVID-19 vaccine candidate. The company was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
Madrid, 28223
:
ISIN: ES0157261019
CUSIP: E6996D109
